Dyadic International Announces Research Collaboration with Sanofi-Aventis
September 07 2018 - 11:18AM
JUPITER, Fla., Sept. 07, 2018 (GLOBE NEWSWIRE)
-- Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global
biotechnology company focused on further improving and applying its
proprietary C1 gene expression platform to speed up the development
and lower the cost of biologic vaccines and drugs at flexible
commercial scales, today announced that it has entered into a fully
funded proof of concept research collaboration to explore the
potential of its C1 technology to produce multiple types of
biologic vaccines and drugs of interest for human health
indications with Sanofi-Aventis Deutschland GmbH, a company of the
Sanofi group, one of the World’s top tier biopharmaceutical
companies.
“We are very pleased to have the opportunity to
collaborate with Sanofi to express multiple types of important
therapeutic compounds using our C1 production platform,” said Mark
Emalfarb, Dyadic’s CEO. “This research and development program is
aiming to overcome specific gene expression challenges and to
further demonstrate the potential of C1 to become a platform of
choice for manufacturing protein-based biologics because of its
speed of development and low cost of goods.”
Under the agreement, Sanofi will fund the
collaborative research which will utilize the proprietary and
patented C1 Gene Expression Platform Technology to express multiple
genes for vaccine and drug applications. The research is expected
to be completed in the second half of 2019. Other terms of
the research collaboration are confidential.
About Dyadic International,
Inc.
Dyadic International, Inc. is a global
biotechnology company which is developing what it believes will be
a potentially significant biopharmaceutical gene expression
platform based on the fungus Myceliophthora thermophila, named C1.
The C1 microorganism, which enables the development and large scale
manufacture of low cost proteins, has the potential to be further
developed into a safe and efficient expression system that may help
speed up the development, lower production costs and improve the
performance of biologic vaccines and drugs at flexible commercial
scales. Dyadic is using the C1 technology and other technologies to
conduct research, development and commercial activities for the
development and manufacturing of human and animal vaccines (such as
virus like particles (VLPs) and antigens), monoclonal antibodies,
Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or
biobetters, and other therapeutic proteins. Dyadic pursues research
and development collaborations, licensing arrangements and other
commercial opportunities with its partners and collaborators to
leverage the value and benefits of these technologies in
development and manufacture of biopharmaceuticals. In particular,
as the aging population grows in developed and undeveloped
countries, Dyadic believes the C1 technology may help bring
biologic drugs to market faster, in greater volumes, at lower cost,
and with new properties to drug developers and manufacturers and,
hopefully, improve access and cost to patients and the healthcare
system, but most importantly save lives.
Please visit Dyadic’s website at
http://www.dyadic.com for additional information, including details
regarding Dyadic’s plans for its biopharmaceutical business.
Dyadic trades on the OTCQX tier of the OTC
marketplace. Investors can find real-time quotes, market
information and financial reports for Dyadic in the Company’s
annual and quarterly reports which are filed with the OTC markets.
Please visit the OTC markets website at
www.otcmarkets.com/stock/DYAI/quote.
Safe Harbor Regarding Forward-Looking
Statements
This press release contains forward-looking
statements. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms
such as “anticipate,” “believe,” “could,” “estimate,” “expect,”
“goal,” “intend,” “look forward to,” “may,” “plan,” “potential,”
“predict,” “project,” “should,” “will,” “would” and similar
expressions. Forward-looking statements are based on management’s
beliefs and assumptions and on information available to management
only as of the date of this press release. These forward-looking
statements involve risks, uncertainties and other factors that
could cause Dyadic’s actual results, performance or achievements to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking
statements. Investors are urged to consider these factors carefully
in evaluating the forward-looking statements and are cautioned not
to place undue reliance on such forward-looking statements. Dyadic
expressly disclaims any intent or obligation to update or revise
any forward-looking statements to reflect actual results, any
changes in expectations or any change in events. Factors that could
cause results to differ materially include, but are not limited to:
(1) general economic, political and market conditions; (2) our
ability to generate the required productivity, stability, purity,
performance, cost, safety and other data necessary to carry out and
implement our biopharmaceutical research and business plans and
strategic initiatives; (3) our ability to retain and attract
employees, consultants, directors and advisors; (4) our ability to
implement and successfully carry out Dyadic’s and third parties
research and development efforts; (5) our ability to obtain new
license and research agreements; (6) our ability to maintain our
existing access to, and/or expand access to third party contract
research organizations in order to carry out our research projects
for ourselves and third parties; (7) competitive pressures and
reliance on key customers and collaborators; (8) the pharmaceutical
and biotech industry, governmental regulatory and other agencies'
willingness to adopt, utilize and approve the use of the C1 gene
expression platform; and (9) other factors discussed in Dyadic’s
publicly available filings, including information set forth under
the caption “Risk Factors” in our December 31, 2017
Annual Report filed with the OTC Markets on March 27, 2018,
and our March 31, 2018 Quarterly Report filed with the OTC Markets
on May 10, 2018. New risks and uncertainties arise from time to
time, and it is impossible for us to predict these events or how
they may affect us.
Contact:
Dyadic International, Inc.
Ping W. Rawson
Chief Accounting Officer
Phone: (561) 743-8333
Email: prawson@dyadic.com
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From Apr 2023 to Apr 2024